Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Joins Clinical Trials Transformation Initiative

PR Newswire October 13, 2021

MindMed Announces Strategic Research Collaboration with Sphere Health

PR Newswire October 5, 2021

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

PR Newswire September 30, 2021

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

PR Newswire September 29, 2021

MindMed to present at the Benzinga Healthcare Small Cap Conference

PR Newswire September 28, 2021

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

PR Newswire September 23, 2021

MindMed Announces Participation at Upcoming Investor Conferences

PR Newswire September 21, 2021

MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire September 10, 2021

MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference

PR Newswire September 9, 2021

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

PR Newswire September 2, 2021

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

PR Newswire August 24, 2021

MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium

PR Newswire August 17, 2021

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

PR Newswire August 12, 2021

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

PR Newswire August 10, 2021

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

PR Newswire August 3, 2021

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

PR Newswire July 28, 2021

MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit

PR Newswire July 12, 2021

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

PR Newswire July 8, 2021

MindMed Included in FTSE Russell 3000® Index

PR Newswire June 28, 2021

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

Canada NewsWire June 23, 2021